{"schema_version":"secwatch.filing_event.v1","accession":"0001420720-23-000065","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2023-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.013069+00:00","generated_at":"2026-06-07T20:57:57.890250+00:00","sec_items":["3.03","5.03","5.02","5.07","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"iBio effects 1-for-20 reverse stock split, reduces outstanding shares from 28.1M to 1.4M","bullets":["Reverse stock split at 1:20 effective 12:01 a.m. ET Nov 29, 2023; shares continue trading as IBIO.","Outstanding shares reduced from 28,100,733 to 1,405,036; fractional shareholders to receive cash.","Stockholders approved reverse split with 5.8M for vs 5.2M against at Nov 27 annual meeting.","Also adopted 2023 Omnibus Incentive Plan and elected directors Clark and Sender.","New CUSIP number is 451033708; transfer agent Continental Stock Trust handling exchanges."],"urls":{"canonical":"https://secwatch.observer/filing/0001420720-23-000065","json":"https://secwatch.observer/filing/0001420720-23-000065.json","markdown":"https://secwatch.observer/filing/0001420720-23-000065.md","text":"https://secwatch.observer/filing/0001420720-23-000065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000065/0001420720-23-000065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000065/ibio-20231127x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T20:57:57.890250+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"77472ee73845f84315f38f60486bc2aff0da3961","claim":"iBio, Inc.: Certificate of Incorporation amended to effect a 1-for-20 reverse stock split, effective November 29, 2023 (effective 2023-11-28).","evidence_excerpt":"On November 28, 2023, the Company filed an amendment to the Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect the reverse stock split, with an effective time of 12:01 a.m. Eastern Time on November 29, 2023 (the “Reverse Stock Split”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000065/0001420720-23-000065-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-11-28"}],"fact_type":"governance_change"},{"claim_id":"43b9c7e9d6cfa0f3fa707988f0815abab24513ec","claim":"iBio, Inc. shareholders approved Approval of adjournment of the 2023 Annual Meeting at the 2023-11-27 meeting.","evidence_excerpt":"The stockholders approved the adjournment of the 2023 Annual Meeting, based on the votes set forth below; however, an adjournment was not needed as Proposals 4 and 5 received a sufficient number of votes for approval.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000065/0001420720-23-000065-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-27"}],"fact_type":"shareholder_vote"},{"claim_id":"90c8f86dc56b18b824afb312c9aad682f29af0ba","claim":"iBio, Inc. shareholders approved Approval of amendment to Certificate of Incorporation for reverse stock split range of 1-for-5 to 1-for-20 at the 2023-11-27 meeting.","evidence_excerpt":"The stockholders approved an amendment to the Company’s Certificate of Incorporation, at a ratio of 1-for-5 to 1-for-20 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board and included in a public announcement.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000065/0001420720-23-000065-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-27"}],"fact_type":"shareholder_vote"},{"claim_id":"9f0f539435287caddb0feeecb0422306ab44a779","claim":"iBio, Inc. shareholders approved Advisory vote on executive compensation at the 2023-11-27 meeting.","evidence_excerpt":"The stockholders approved, on an advisory, non-binding basis, the compensation of the Company’s named executive officers (\"say-on-pay\"), as disclosed in the Definitive Proxy Statement.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000065/0001420720-23-000065-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-27"}],"fact_type":"shareholder_vote"},{"claim_id":"c16215e87b6566727e8663f006eda9a70c88e27e","claim":"iBio, Inc. shareholders approved Ratification of CohnReznick LLP as independent registered public accounting firm at the 2023-11-27 meeting.","evidence_excerpt":"The stockholders ratified the appointment of CohnReznick LLP as the Company’s independent registered public accounting firm for the year ending June 30, 2024 based on the votes set forth below:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000065/0001420720-23-000065-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-27"}],"fact_type":"shareholder_vote"},{"claim_id":"c6a806e25f1823dbdeda2233b7d7d3128d697a64","claim":"iBio, Inc. shareholders approved Election of two Class III directors at the 2023-11-27 meeting.","evidence_excerpt":"The following two (2) nominees named as Class III directors of the Company’s Board of Directors, each to serve a three-year term expiring at the 2026 Annual Meeting of Stockholders and until such director’s successor is duly elected and qualified, were elected with the following votes:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000065/0001420720-23-000065-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-27"}],"fact_type":"shareholder_vote"},{"claim_id":"e2901a52262a6d3ef98887b9f16f52e6eb315870","claim":"iBio, Inc. shareholders approved Adoption of the 2023 Plan at the 2023-11-27 meeting.","evidence_excerpt":"The stockholders approved the adoption of the 2023 Plan.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420720/000142072023000065/0001420720-23-000065-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-27"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}